



Analyst Highlights Of Week 14/2015

It's time once again to take a look at what happened in the past week. The following highlights are compiled from research reports released by leading analyst firms. You can also find full stories on our front page or in the archive sections. We are always open for your comments. Please contact us at: info@smarteranalyst.com

Please click on the headline to access the summary.

Healthcare

MEI Pharma Inc (NASDAQ:MEIP)

Cantor Slashes Price Target for MEI Pharma Inc on Increased Risk Profile of Pracinostat - Brims Buy, \$7 PT

Intecept Pharmaceuticals Inc (NASDAQ:ICPT)

Wedbush Maintains Outperform on Intercept Pharmaceuticals Inc on Back of NASH Competition Results - Moussatos Buy

OXIGENE Inc (NASDAQ:OXGN)

H.C. Wainwright Pounds the Table on OXiGENE Inc - Benjamin

Buy, \$6 PT

Cytosorbents Corp (NASDAQ:CTSO)

MLV Reiterates Buy on Cytosorbents Corp Following 4Q:14 Update - Selvaraju

Buy, \$28 PT

Gilead Sciences, Inc. (NASDAQ:GILD)

Maxim Reiterates Buy on Gilead Sciences, Inc. Following Sovaldi Approval in Japan - Kolbert

Buy, \$127 PT

Coronado Biosciences Inc (NASDAQ:CNDO)

MLV Upgrades Coronado Biosciences Inc From Hold to Buy - Bernardino

Buy, \$7 PT

Dyax Corp. (NASDAQ:DYAX)

Oppenheimer Boosts Price Target for Dyax Corp. as DX-2930 Data Results 'Smashes Expectations' - Felt

Buy, \$26 PT

Endocyte, Inc. (NASDAQ:ECYT)

Cantor Pounds The Table On Endocyte, Inc. - Brims

Buy, \$21 PT

Bio Blast Pharma Ltd (NASDAQ:ORPN)

Oppenheimer Maintains Outperform on Bio Blast Pharma Ltd Following Pre-Clinical Updates - Nochomovitz Buy, \$32 PT

Horizon Pharma PLC (NASDAQ:HZNP)

Brean Capital Lifts Price Target for Horizon Pharma PLC Following Acquisition of Hyperion - Yang Buy, \$33 PT

Sarepta Therapeutics Inc (NASDAQ:SRPT)

Oppenheimer Reiterates Outperform on Sarepta Therapeutics Following CEO Resignation - Marai Buy, \$45 PT

Technology

Micron Technology, Inc. (NASDAQ:MU)

Micron Technology, Inc. (MU) Bullish Stance Reiterated at Roth Capital Following 2Q:15 Results - Shankar Buy, \$40 PT

Himax Technologies, Inc. (ADR) (NASDAQ:HIMX)

Brean Capital Maintains Hold on Himax Technologies, Inc. (ADR); Adjusts Estimates - Burton Hold, \$5-\$8.30 PT

Alibaba Group Holding Ltd (NYSE:BABA)

Oppenheimer Offers Commentary on Alibaba Group Holding Ltd Following Recent Business Updates - Ji Buy, \$105 PT

Yingli Green Energy Holding Co. Ltd. (YGE) (NYSE:YGE)

Wolfe Research Initiates Underperform On Yingli Green Energy Holding; Sees 36% Downside For The Stock - Johnson Sell, \$1.19 PT

Palo Alto Networks Inc (NYSE:PANW)

Oppenheimer Offers Commentary on Palo Alto Networks Inc From Networks Ignite User Conference - Eyal Buv

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI)

Brean Capital Offers Commentary on IntelliPharmaCeutics Intl Inc (USA) Following Clincal Updates - Yang Buy, \$8 PT

Skyworks Solutions Inc (NASDAQ:SWKS)

Brean Capital Boosts Price Target for Skyworks Solutions Inc on Increased Confidence - Burton Buy, \$110 PT

Cypress Semiconductor Corporation (NASDAQ:CY)

Needham Reiterates Buy on Cypress Semiconductor Corporation Following Completed Merge With Spansion Inc. Buy, \$20 PT

Basic Materials

Rex Energy Corporation (NYSE:REXX)

Canaccord Genuity Reiterates Hold On Rex Energy Corporation Following Joint Venture With ArcLight - Chalabala Hold, \$7 PT

Rex Energy Corporation (NYSE:MDW)

Canaccord Remains Cautious on Midway Gold Corp (USA) Following First Gold Pour - Chalabala Hold

Transocean LTD (NYSE:RIG)

Canaccord Genuity Maintains Sell on Transocean LTD Following Decrease in Rigs - Brooks Sell, \$10 PT

Marathon Oil Corporation (NYSE:MRO)

Oppenheimer Pounds the Table on Marathon Oil Corporation, Maintains Outperform - Gheit Buy, \$32 PT

Consumer Goods

Apple Inc. (NASDAQ: AAPL)

Apple Could Reach 1 Million Watches Sold Opening Weekend: Piper Jaffray - Munster

Buy, \$160 PT

Financial

American Realty Capital Properties Inc (NASDAQ:ARCP)

American Realty Capital Properties Inc's New CEO Takes Office; Oppenheimer Remains Maintains Perform Rating - Manaker

Hold, \$N/A PT

Ratings System Definitions:

Buy: Stock is expected to outperform against the market over next 12 months.

Hold: Stock is expected to perform in line with the market over next 12 months.

Sell: Stock has more downside risk than upside potential at current prices. Expect shares to underperform the market from current prices.

Outperform: Stock is expected to outperform within its industry over next 12 months.

Market Perform/Neutral: Stock should perform roughly in line with current market. Neither encourages purchase or sale of these securities at current prices.

Underperform: Stock's total return is expected to underperform the industry average over next 12 months.

Overweight: Stock is expected to perform better than the broad market over next 12 months.

Equalweight: Stock is expected to perform in line with broad market over next 12 months. **Underweight:** Stock is expected to perform worse than broad market over next 12 months.

than broad market over next 12 months.